biote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Purchases 436,037 Shares

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc acquired 436,037 shares of the stock in a transaction dated Tuesday, May 6th. The shares were bought at an average cost of $3.26 per share, for a total transaction of $1,421,480.62. Following the acquisition, the insider now owns 4,611,071 shares in the company, valued at $15,032,091.46. The trade was a 10.44 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Guines Llc also recently made the following trade(s):

• On Wednesday, April 30th, Guines Llc bought 1,933 shares of biote stock. The shares were bought at an average cost of $3.30 per share, with a total value of $6,378.90.
• On Monday, April 21st, Guines Llc purchased 8,801 shares of biote stock. The stock was purchased at an average cost of $3.27 per share, for a total transaction of $28,779.27.
• On Thursday, April 17th, Guines Llc acquired 6,874 shares of biote stock. The stock was purchased at an average price of $3.29 per share, with a total value of $22,615.46.
• On Wednesday, April 9th, Guines Llc bought 13,532 shares of biote stock. The stock was purchased at an average price of $3.21 per share, for a total transaction of $43,437.72.
• On Monday, April 7th, Guines Llc bought 43,378 shares of biote stock. The shares were purchased at an average cost of $3.15 per share, with a total value of $136,640.70.
• On Thursday, April 3rd, Guines Llc purchased 7,321 shares of biote stock. The stock was acquired at an average cost of $3.24 per share, for a total transaction of $23,720.04.
• On Monday, March 31st, Guines Llc acquired 106,000 shares of biote stock. The shares were acquired at an average cost of $3.32 per share, with a total value of $351,920.00.
• On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The stock was acquired at an average cost of $3.74 per share, for a total transaction of $374.00.
• On Thursday, March 13th, Guines Llc acquired 750,000 shares of biote stock. The stock was acquired at an average cost of $3.22 per share, with a total value of $2,415,000.00.

biote Stock Performance

Shares of BTMD opened at $3.74 on Friday. The company has a 50-day simple moving average of $3.61 and a 200-day simple moving average of $4.94. biote Corp. has a 52 week low of $3.04 and a 52 week high of $8.44. The firm has a market capitalization of $204.62 million, a P/E ratio of 14.38 and a beta of 1.17.

biote (NASDAQ:BTMD) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. biote had a negative return on equity of 32.41% and a net margin of 5.20%. The firm had revenue of $48.99 million during the quarter, compared to analysts’ expectations of $47.25 million. As a group, equities analysts forecast that biote Corp. will post 0.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Craig Hallum dropped their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD bought a new position in shares of biote during the 4th quarter worth about $67,000. Commonwealth Equity Services LLC acquired a new position in biote in the fourth quarter worth about $68,000. Public Employees Retirement System of Ohio bought a new position in biote during the fourth quarter worth about $69,000. Intech Investment Management LLC bought a new stake in shares of biote in the 4th quarter valued at approximately $71,000. Finally, SG Americas Securities LLC acquired a new position in shares of biote in the 4th quarter worth approximately $76,000. 21.68% of the stock is owned by institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.